Vera Therapeutics (VERA) Stock Forecast & Price Target

Vera Therapeutics is well-positioned for success with their product candidate atacicept, which has the potential to address a significant unmet need in the treatment of autoimmune diseases. Their regulatory strategies are in line with industry standards and they have ample funding to support their operations through potential approval and commercial launch. Their 2Q26 financial update reported no revenue, but they are projected to have total revenues of $16M and a net loss of $6.52 per diluted share for 2026, indicating their potential for long-term profitability once atacicept is on the market.

Vera Therapeutics is a clinical-stage biotechnology company that specializes in developing transformative treatments for serious immunological diseases. With a focus on atacicept, a drug that blocks B-cells and plasma cells from producing autoantibodies that contribute to autoimmune diseases, the company aims to target APRIL to preserve kidney function. However, recent data from Otsuka's Voyxact drug has shown superior results, and with some concerns over Trutakna's commercial potential, the company's revenue forecast has been lowered for the next three quarters. This, combined with an increasingly competitive IgAN market and a higher discount rate, leads to a Neutral rating and a revised price target of $34.